Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2 and PDGFRß - Sharma, S; Miller, L; Gordon, M
Poster presentation at 22nd EORTC-NCI-AACR symposium on Molecular targets and Cancer Therapeutics November 16–19, Berlin, 2010, Abstract no: 400